Top Page
EVE Health Group Limited
(Sydney:EVE)
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
EVE Health Group Limited Business Overview & Revenue Model
EVE Health Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.73M | 1.73M | 2.13M | 2.33M | 2.01M | 2.80M |
| Gross Profit | 824.03K | 824.03K | 876.96K | 827.83K | -1.00M | -713.50K |
| EBITDA | -1.45M | -1.43M | -1.51M | -2.18M | -4.53M | -3.26M |
| Net Income | -1.58M | -1.58M | -1.90M | -4.04M | -5.37M | -3.63M |
Balance Sheet | ||||||
| Total Assets | 4.12M | 4.12M | 2.52M | 4.13M | 8.07M | 11.92M |
| Cash, Cash Equivalents and Short-Term Investments | 903.42K | 903.42K | 106.17K | 192.48K | 1.10M | 3.16M |
| Total Debt | 91.28K | 91.28K | 74.85K | 4.28K | 492.39K | 1.01M |
| Total Liabilities | 572.45K | 572.45K | 1.30M | 1.01M | 1.14M | 1.74M |
| Stockholders Equity | 3.55M | 3.55M | 1.22M | 3.12M | 6.93M | 10.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.62M | -1.62M | -1.11M | -1.65M | -3.80M | -2.51M |
| Operating Cash Flow | -1.62M | -1.62M | -1.11M | -1.65M | -3.77M | -2.24M |
| Investing Cash Flow | 2.13M | 2.13M | 874.27K | 498.46K | -26.05K | -263.38K |
| Financing Cash Flow | 279.09K | 279.09K | 146.37K | 240.69K | 1.74M | 529.43K |
EVE Health Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
43 Neutral | AU$27.14M | 35.22 | ― | ― | 6.76% | ― | |
43 Neutral | ― | ― | ― | ― | ― | 27.69% | |
42 Neutral | AU$8.02M | -2.78 | -77.48% | ― | 63.30% | 70.00% | |
41 Neutral | AU$7.07M | ― | -60.84% | ― | -18.70% | 20.83% | |
37 Underperform | AU$12.23M | -6.67 | -555.97% | ― | 88.48% | 51.61% | |
31 Underperform | AU$4.07M | -0.58 | ― | ― | -21.84% | 79.99% |
EVE Health Group Limited Corporate Events
EVE Health Group announced that all resolutions presented at its Annual General Meeting were passed by a poll. This includes the adoption of the remuneration report, the re-election of a director, approval of an additional 10% capacity, and the issuance of securities under an employee incentive plan. These decisions reflect strong shareholder support and could positively impact the company’s strategic initiatives and market positioning.
EVE Health Group Limited has announced a General Meeting of Shareholders to be held on December 4, 2025, in Subiaco, Western Australia. Shareholders are encouraged to participate by attending in person or voting by proxy, with proxy forms to be submitted 48 hours prior to the meeting. This meeting is a crucial event for shareholders to engage with the company’s governance and decision-making processes.
EVE Health Group Limited has announced the issuance of up to 12,300,000 unlisted options to key personnel and directors as part of its Employee Incentive Plan. This initiative aims to align compensation with shareholder value creation, support talent retention, and focus on achieving key commercial and regulatory milestones in its health portfolios. The options, which require shareholder approval for directors, have specific vesting conditions tied to service and performance targets, including share price milestones and product registrations.
EVE Health Group Limited has appointed its first dedicated Medical Science Liaison (MSL) to lead national medical education and engagement programs, marking a significant step in its commercial rollout strategy. This appointment aims to build confidence among prescribers and broaden patient access to EVE’s products, Dyspro™ and Libbo™, with plans to expand the MSL team throughout 2026, enhancing the company’s medical capability and supporting its growth in the pharmaceutical industry.
EVE Health Group Limited announced significant progress in the commercial rollout of its products Dyspro™ and Libbo™. The company has completed the first patient prescriptions for Dyspro™, a cannabinoid-based gummy for women’s health issues, and placed its first commercial order for Libbo™, an oral dissolving film for erectile dysfunction. EVE has also launched an online platform, Reclaim My Cycle, to support women’s health education and prescriber resources. Additionally, a $1.1 million placement was completed to accelerate these initiatives, and a Scientific Advisory Board was established to guide the company’s evidence-based strategy.
EVE Health Group Limited has announced a target market determination for the issuance of free attaching options related to a placement offer of shares to sophisticated investors. The options, which include Attaching Placement Options, Lead Manager Options, and Attaching Corporate Adviser Options, are designed for investors seeking exposure to the company’s growth in the health and pharmaceutical sectors. These options are part of a strategy to raise $1,100,000 through a share placement, with the potential for capital growth and inclusion in a diversified portfolio for medium to long-term investment. The options are not intended to be quoted, and the company emphasizes the importance of consulting the prospectus and professional advisers before making investment decisions.
EVE Health Group Limited has issued a prospectus detailing several offers, including the issuance of 36,666,667 Placement Shares to raise $1,100,000, alongside options for placement subscribers and corporate advisers. These offers are subject to shareholder approval and are aimed at enhancing the company’s financial position and market presence. The prospectus is a transaction-specific document prepared in accordance with the Corporations Act, and it highlights the importance of potential investors considering their financial objectives and risks before investing.
EVE Health Group Limited has announced a proposed issue of securities, including options exercisable at AUD 6 cents expiring in two years, and ordinary fully paid shares. This move is part of a placement or other type of issue, potentially impacting the company’s financial strategy and market positioning.
EVE Health Group Limited has successfully raised $1.1 million through a placement to sophisticated and professional investors, exceeding their initial target due to strong investor demand. The funds will be used to accelerate the commercial rollout of their lead pharmaceutical products, Dyspro and Libbo, by expanding prescriber education programs, growing distribution networks, and supporting marketing and patient access initiatives. This financial boost is expected to enhance EVE’s market positioning and facilitate the progression to TGA Export-Only status and full TGA registration, reflecting strong confidence in the company’s strategy to transform treatment in women’s and men’s health.
EVE Health Group Limited has requested a trading halt on its securities as it plans to consider, plan, and execute a capital raising. The trading halt will remain in effect until either the start of normal trading on 9 October 2025 or when the company makes an announcement regarding the capital raising. This move indicates EVE’s strategic financial planning and could impact its market operations and stakeholder interests.
EVE Health Group Limited has announced its Annual General Meeting (AGM) for shareholders, scheduled to take place on November 5, 2025, in Subiaco, Western Australia. Shareholders are encouraged to participate by attending in person or voting by proxy, with proxy forms to be submitted 48 hours prior to the meeting. This AGM is a significant event for the company, providing a platform for shareholder engagement and decision-making on key corporate matters.
EVE Health Group Limited has announced the launch of two innovative products, Dyspro and Libbo, targeting the global dysmenorrhoea and erectile dysfunction markets, valued at US$10.92B and US$5.31B respectively. With its patent-pending nano-emulsion technology, the company aims to improve drug delivery speed and effectiveness, having already commenced sales of Dyspro in Australia, with Libbo expected to follow in December.
EVE Health Group announced that its incoming CEO, Mr. Damian Wood, will present at the ShareCafe Small Cap ‘Sip and Learn’ Webinar on September 25, 2025. This presentation marks a significant engagement opportunity for the company, potentially impacting its market visibility and stakeholder relations positively.
EVE Health Group Limited has announced the successful manufacture and distribution of Dyspro™, a cannabinoid-based gummy designed to address dysmenorrhoea and endometriosis, two significant women’s health issues. The product is now available for prescription through TeleDocs’ telehealth network, with additional distribution pathways being explored. This launch marks a pivotal moment for EVE as it aims to meet the substantial unmet medical needs in this market, which is expected to grow significantly in the coming years.
EVE Health Group Limited has announced that its next Annual General Meeting (AGM) will be held on or about November 6, 2025, with the re-election of directors as a key agenda item. The deadline for director nominations is set for September 18, 2025. This announcement is crucial for stakeholders as it outlines the timeline for potential changes in the company’s leadership, which could impact its strategic direction and operations.
EVE Health Group Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to ASX Corporate Governance Council’s principles, confirming compliance with key governance recommendations, which enhances transparency and accountability to stakeholders.
EVE Health Group reported a 19% decrease in revenue from ordinary activities for the financial year ending June 30, 2025, compared to the previous year. The company also saw a 17% reduction in net loss attributable to members, with no dividends declared during the period. Despite the financial downturn, EVE Health Group continues to focus on its core operations in the health sector, aiming to strengthen its market position through its subsidiaries.
EVE Health Group Limited has announced the submission of its first commercial purchase order for Libbo™, an oral dissolving film formulation for treating erectile dysfunction. This marks a significant milestone for EVE’s pharmaceutical division, as Libbo™ is set to be available for prescription by the end of 2025. The product offers a discreet, convenient, and fast-acting alternative to traditional ED treatments, potentially enhancing patient compliance and satisfaction. With no further regulatory steps required, the manufacturing process will commence immediately, and the shipment is expected in Q4 2025. The global erectile dysfunction treatment market is valued at over USD $5.3 billion and is expected to grow, positioning EVE to capitalize on this expanding market.